SWOG S1107: Parallel (Randomized) Phase II Evaluation of ARQ197 and ARQ197 in combination with Erlotinib in Papillary Renal cell Carcinoma

Objective

This is a clinical trial of ARQ 197 that will be administered by mouth which is investigational and erlotinib that will be administered by mouth and is standard of care.

IRB Protocol Number

13-0002

Principal Investigator(s)

ELAINE LAM

Cancer Trials

• Kidney Cancer

Sponsor(s)

SWOG

Contact

NICOLE CHRONISTER at 720-848-0602
or NICOLE.CHRONISTER@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period(s) that can last up to three years. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with papillary kidney cancer.